Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWL6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $77,329
Award facts
- Contract value 100% obligated
- $77,328.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $77,328.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 21, 2026, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal military medical supply chain since its SAM registration in July 2001. The company's prime vendor contract, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, with a completion date of December 31, 2036, positioning the contractor as one of multiple regional prime vendors authorized to deliver firm fixed-price orders for branded and generic prescription drugs, biologics, vaccines, and medical consumables. The contractor's demonstrated performance across numerous delivery orders spanning diverse therapeutic categories—including oncology treatments, immunosuppressants, vaccines, and specialty pharmaceuticals—underscores its role as a key supplier supporting ongoing Department of Defense military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FQWL6?
SPE2DR26FQWL6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FQWL6 worth?
The government has obligated $77,329 on SPE2DR26FQWL6.
Is contract SPE2DR26FQWL6 an order under another contract?
Yes. SPE2DR26FQWL6 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWL6 competed?
The extent of competition for SPE2DR26FQWL6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award